Ascendis Pharma A (ASND) Cash from Financing Activities (2014 - 2026)

Ascendis Pharma A has reported Cash from Financing Activities for 13 years, with the latest figure at -$43.1 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 127.45% year-over-year to -$43.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.1 million (down 90.61% YoY) and the FY2025 annual result came in at $64.3 million, down 86.45% from the prior year.
• Cash from Financing Activities eased to -$43.1 million in Q1 2026 per ASND's latest filing, from $31.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $469.9 million in Q3 2024 and troughed at -$43.1 million in Q1 2026.
• A 5-year average of $64.8 million and a median of $92967.8 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 1850254.95% in 2022, then slumped 573.35% in 2023.
• Over 5 years, Cash from Financing Activities stood at $1.4 million in 2022, then plunged by 573.35% to -$6.5 million in 2023, then jumped by 101.43% to $92967.8 in 2024, then jumped by 34212.36% to $31.9 million in 2025, then sank by 235.18% to -$43.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$43.1 million, $31.9 million, and $45.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.